Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018133 (graft-versus-host disease)
 18,032 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Alloimmunization of BALB/c (H-2d) female mice with allogeneic spleen cells from C57BL/6 (H-2b) or CBA/H (H-2k) mice protects BALB/c offspring from graft-versus-host disease (GVH-D) following neonatal intraperitoneal inoculation of high doses of spleen cells respectively of C57BL/6 or CBA/H strains of mice. The mice survived GVH-D over one year after the allogeneic inoculum 24-48 h after birth and they did not show any signs of GVH reaction nor splenomegaly. We show that this phenomenon is antibody mediated and affects the developing immune system of the foetus. Repeated immunization of virgin female BALB/c with anti-H-2b or anti-H-2k antisera (Ab1) can equally abrogate GVH-D in their newborn offspring challenged at 24-48 h after birth with allogeneic spleen cells of H-2b or H-2k phenotype. Our results demonstrate that protection from GVH-D is not specific to the immunizing strain and occurs when the neonatal mice are challenged with C57BL/6 or CBA/H spleen cells. There is thus crossreactivity of tolerance against H-2 specificities. In this study we also report on the in vitro cellular immune responses of the surviving GVH-resistant mice and demonstrate that these responses against both the challenge and third party lymphocytes are impaired.
 ...
PMID:Protection of newborn mice from graft versus host disease by maternal pre-immunization. 221 2

Transplanted immunocompetent cells from CBA (H-2k) mice immunized against individual or pooled lymphoid cells from various allogeneic strains resulted in the elimination of widely disseminated leukemia cells in AKR (H-2k) host mice as measured in a GVL bioassay. In most cases, alloimmunization resulted in reactivity against AKR-L comparable to that observed when CBA donors were specifically immunized with irradiated AKR-L cells. Cells from unimmunized or isoimmunized CBA mice had no detectable GVL reactivity. Alloimmunization caused no increase in the mild GVH reactivity of unimmunized or isoimmunized CBA lymphoid cells transplanted into lethally irradiated nonleukemic AKR hosts; whereas, specific immunization with AKR-LX cells resulted in significantly increased GVH-related mortality.
 ...
PMID:Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice. 696 95

Advances in platelet transfusion have contributed to improved outcomes in the treatment of patients with cancer and leukemia. However, the optimal strategies to avoid some of the side effects that could result from platelet transfusions remain under investigation. These side effects include the development of refractoriness to transfusions, alloimmunization, transfusion reactions, the transmission of infectious agents, and transfusion-associated graft-versus-host disease. Leukodepletion by filtration is promising as a means of preventing the development of alloimmunization. Results of the Trial to Reduce Alloimmunization to Platelets will be reported shortly and will shed more light on that issue. Bedside filtration of cellular blood products also diminishes the transmission of cytomegalovirus infections by that route. Transfusion reactions are often mediated by cytokines in the plasma fraction of transfused platelet concentrates, and leukodepletion prior to storage reduces their incidence. Serious bacterial infections are sometimes transmitted by platelet transfusions and improved methods are needed for their detection and prevention. Photochemical methods that could inactivate bacteria and viruses in contaminated products deserve further study.
 ...
PMID:Platelet transfusion support for patients with cancer and hematologic malignancies. 937

Functional white blood cells (WBCs) in blood components may be responsible for a number of adverse transfusion effects, including transfusion-associated graft-versus-host disease (TA-GVHD), alloimmunization, and alloimmune platelet (PLT) refractoriness. TA-GVHD occurs when functional lymphocytes are transfused into a patient who is unable to mount an immune response to the human leukocyte antigen (HLA) due to HLA compatibility or immunosuppression. Alloantibodies against HLA antigens on donor WBCs and PLTs are the major cause of refractoriness to PLT transfusions in patients receiving repeated blood transfusions. Attempts to reduce these undesirable effects have included leukoreduction filters and gamma irradiation. Studies have shown that exposure of PLT concentrates to riboflavin and light (Mirasol pathogen reduction technology [PRT], CaridianBCT Biotechnologies) causes irreparable modifications of nucleic acids that result in inactivation of a wide range of pathogens as well as inhibition of the immunologic responses mediated by WBCs present in PLT concentrates. This article summarizes these studies and also reports on additional findings from the Trial to Reduce Alloimmunization to Platelets (TRAP) and Mirasol Clinical Evaluation (MIRACLE) trials. Data from in vitro studies and this clinical trial suggest that PRT treatment may be as effective as gamma irradiation in preventing TA-GVHD and more effective than leukoreduction in preventing alloimmunization.
 ...
PMID:White blood cell inactivation after treatment with riboflavin and ultraviolet light. 2052 2

Hemopoietic stem-cell transplant patients may require intensive blood component support. Complications of transfusions include transmission of viral and bacterial infections, transfusion-associated graft-versus-host disease and transfusion-related acute lung injury. Alloimmunization to red cell antigens may cause difficulties in selecting compatible blood, while alloimmunization to HLA expressed on platelets may cause subsequent platelet transfusion refractoriness. It is essential to define robust transfusion policies and procedures and these should be regularly audited. This article reviews blood component transfusion in the setting of hemopoietic stem-cell transplant and specifically discusses the management of ABO-mismatched transplants, the prevention of cytomegalovirus transmission, the prevention of transfusion-associated graft-versus-host disease and the use of granulocyte transfusions.
 ...
PMID:Transfusion strategies in patients undergoing stem-cell transplantation. 2149 30